Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) is expected to post its quarterly earnings results before the market opens on Thursday, March 27th. Analysts expect Unicycive Therapeutics to post earnings of ($0.13) per share for the quarter.
Unicycive Therapeutics Price Performance
Shares of UNCY stock opened at $0.64 on Tuesday. The stock’s fifty day moving average price is $0.59 and its 200 day moving average price is $0.56. Unicycive Therapeutics has a 1-year low of $0.20 and a 1-year high of $1.60. The company has a market cap of $66.75 million, a price-to-earnings ratio of -0.66 and a beta of 2.26.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright restated a “buy” rating and set a $4.00 price target on shares of Unicycive Therapeutics in a research note on Wednesday, January 29th.
Unicycive Therapeutics Company Profile
Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.
Recommended Stories
- Five stocks we like better than Unicycive Therapeutics
- 3 Monster Growth Stocks to Buy Now
- Super Micro Stock: $7.2M Call Options Signal Big Upside Potential
- 3 REITs to Buy and Hold for the Long Term
- Top 3 Buy-and-Hold Stocks for 2025: Long-Term Winners to Watch
- The Basics of Support and Resistance
- D-Wave Stock: Is Quantum Blockchain the Next Big Catalyst?
Receive News & Ratings for Unicycive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unicycive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
